CRISPR Therapeutics (Nasdaq: CRSP) presented one-year follow-up data from its Phase 1a clinical trial of CTX310, an investigational in vivo ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE